PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

PharmaTher has announced that the U.S. Food and Drug Administration (“FDA”) has accepted an investigator-initiated investigational new drug (“IND”) application to proceed with a Phase 2 clinical trial (the “Study”) evaluating ketamine in the treatment of Amyotrophic Lateral Sclerosis (“ALS”), also known as Lou Gehrig’s disease. The Study will be conducted at the University of Missouri led by the Study’s Primary Investigator, Dr. Richard Barohn, M.D.

Category Press Release
Published in GlobeNewswire